Ad is loading...
ENTA
Price
$9.31
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
2 days until earnings call
KROS
Price
$53.84
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
96 days until earnings call
Ad is loading...

ENTA vs KROS

Header iconENTA vs KROS Comparison
Open Charts ENTA vs KROSBanner chart's image
Enanta Pharmaceuticals
Price$9.31
Change-$0.00 (-0.00%)
Volume$264.39K
CapitalizationN/A
Keros Therapeutics
Price$53.84
Change-$0.00 (-0.00%)
Volume$349.16K
CapitalizationN/A
ENTA vs KROS Comparison Chart
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KROS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ENTA vs. KROS commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and KROS is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (ENTA: $9.34 vs. KROS: $55.92)
Brand notoriety: ENTA and KROS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 542% vs. KROS: 97%
Market capitalization -- ENTA: $197.9M vs. KROS: $2.27B
ENTA [@Biotechnology] is valued at $197.9M. KROS’s [@Biotechnology] market capitalization is $2.27B. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.6B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileKROS’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • KROS’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTA is a better buy in the long-term than KROS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 5 bullish TA indicator(s).

  • ENTA’s TA Score: 4 bullish, 6 bearish.
  • KROS’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, KROS is a better buy in the short-term than ENTA.

Price Growth

ENTA (@Biotechnology) experienced а -1.99% price change this week, while KROS (@Biotechnology) price change was -1.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

ENTA is expected to report earnings on Feb 05, 2025.

KROS is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KROS($2.27B) has a higher market cap than ENTA($198M). KROS YTD gains are higher at: 40.644 vs. ENTA (-0.744). ENTA has higher annual earnings (EBITDA): -104.08M vs. KROS (-185.94M). KROS has more cash in the bank: 531M vs. ENTA (230M). KROS has less debt than ENTA: KROS (19.3M) vs ENTA (50.6M). ENTA has higher revenues than KROS: ENTA (72M) vs KROS (651K).
ENTAKROSENTA / KROS
Capitalization198M2.27B9%
EBITDA-104.08M-185.94M56%
Gain YTD-0.74440.644-2%
P/E RatioN/AN/A-
Revenue72M651K11,060%
Total Cash230M531M43%
Total Debt50.6M19.3M262%
FUNDAMENTALS RATINGS
ENTA: Fundamental Ratings
ENTA
OUTLOOK RATING
1..100
62
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ENTAKROS
RSI
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 13 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 5 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KROS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FASEX61.390.64
+1.05%
Nuveen Mid Cap Value 1 A
BMPSX102.530.85
+0.84%
ProFunds Materials UltraSector Svc
NSOIX18.190.11
+0.61%
North Star Opportunity I
MEFYX21.13N/A
N/A
MassMutual Mid Cap Growth Svc
TAAHX36.48N/A
N/A
Transamerica Multi-Managed Balanced R

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with INZY. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+0.32%
INZY - ENTA
42%
Loosely correlated
+4.46%
ARWR - ENTA
41%
Loosely correlated
+1.42%
ETNB - ENTA
41%
Loosely correlated
+4.53%
GBIO - ENTA
40%
Loosely correlated
+3.79%
KROS - ENTA
39%
Loosely correlated
+3.86%
More

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with KYMR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+3.86%
KYMR - KROS
46%
Loosely correlated
+3.38%
COGT - KROS
43%
Loosely correlated
+1.67%
AXON - KROS
43%
Loosely correlated
+0.90%
INZY - KROS
43%
Loosely correlated
+4.46%
AKRO - KROS
43%
Loosely correlated
+4.90%
More